TOP TEN perturbations for 1553645_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553645_at
Selected probe(set): 1553645_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553645_at (1553645_at) across 6672 perturbations tested by GENEVESTIGATOR:

bicalutamide study 1 / dihydrotestosterone study 1

Relative Expression (log2-ratio):-4.485307
Number of Samples:3 / 3
Experimental bicalutamide study 1
Bicalutamide treated (10mM) human prostate carcinoma LNCaP cells, stimulated with dihydrotestosterone (DHT). Bicalutamide was added 2 h before DHT stimulation. ATC code:
Control dihydrotestosterone study 1
Human prostate carcinoma LNCaP cells stimulated with dihydrotestosterone (DHT; INN: androstanolone; 1nM; 16h). ATC code:

dihydrotestosterone study 1 / untreated LNCaP cell sample

Relative Expression (log2-ratio):4.4808702
Number of Samples:3 / 2
Experimental dihydrotestosterone study 1
Human prostate carcinoma LNCaP cells stimulated with dihydrotestosterone (DHT; INN: androstanolone; 1nM; 16h). ATC code:
Control untreated LNCaP cell sample
Untreated human prostate carcinoma LNCaP cells not stimulated with dihydrotestosterone (DHT).

OVCAR-8 RIIB / OVCAR-8

Relative Expression (log2-ratio):4.1042056
Number of Samples:3 / 3
Experimental OVCAR-8 RIIB
Human metastatic cancer cell line derived from the ascites fluid from a cisplatin-resistant patient with carcinoma of the ovary. Stably transfected with the cAMP-dependent protein kinase (PKA) regulatory subunit gene for RII╬▓. Parental cell line:: OVCAR-8 Cellosaurus code:
Control OVCAR-8
Human metastatic cancer cell line derived from the ascites fluid from a cisplatin-resistant patient with carcinoma of the ovary. Synonyms:NIH:OVCAR-8; OVCAR8; Ovcar8; OVCAR.8; OVCA8 Cellosaurus code:

dexamethasone study 9 (24h) / EtOH treated CCRF-CEM-C7H2 cell sample

Relative Expression (log2-ratio):3.8309307
Number of Samples:3 / 3
Experimental dexamethasone study 9 (24h)
CCRF-CEM-C7H2 cells cultured in the presence of dexamethansone (10e-7M) for 24 hours. ATC code:, , , , , , , , , ,
Control EtOH treated CCRF-CEM-C7H2 cell sample
CCRF-CEM-C7H2 cells treated for 24 hours with 0.1% ethanol (EtOH) as carrier control.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-3.8298483
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):3.7540293
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

DLBCL study 7 (ABC; naive-like) / DLBCL study 7 (ABC; memory-like)

Relative Expression (log2-ratio):2.8350859
Number of Samples:2 / 5
Experimental DLBCL study 7 (ABC; naive-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (activated B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to naive-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.
Control DLBCL study 7 (ABC; memory-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (activated B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to memory-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (10d)

Relative Expression (log2-ratio):-2.8273034
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (10d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to hepatic specification stage for 10 days.

lung adenocarcinoma study 5 (EML4-ALK) / adjacent lung tissue

Relative Expression (log2-ratio):-2.6335726
Number of Samples:3 / 20
Experimental lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

lung adenocarcinoma study 6 (K-RAS mut) / adjacent lung tissue

Relative Expression (log2-ratio):-2.6312237
Number of Samples:6 / 20
Experimental lung adenocarcinoma study 6 (K-RAS mut)
Primary tumor sample from patients with stage II adenocarcinoma carrying a K-RAS mutation.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.